Angelini Pharma Company

Media

Angelini Pharma Company
  • Home
  • About Us
  • About Epilepsy
  • Media
    • Press Release
  • Contact
  • News + Press Releases
  • 2021
  • 2020
  • 2019

New study demonstrates the safety and tolerability of treatment with cenobamate tablets in adults with focal seizures

The results of the long-term, open-label extension (OLE) of a randomized, double-blind, placebo-controlled study of cenobamate (C013) have been…

Read more July 26, 2021

Angelini Pharma finalizes the acquisition agreement

• Through this acquisition, Angelini Pharma will be a major player in the market of companies focused on the treatment of central nervous system…

Press Release February 2, 2021

ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults*

Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate When approved, cenobamate will provide new hope in helping…

Press Release January 29, 2021

Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments

Angelini Pharma and Arvelle Therapeutics have today agreed on a definitive merger agreement valuing Arvelle Therapeutics at up to $960 million…

Press Release January 4, 2021

Arvelle Announces Partnership with Durbin Across Europe

Zug, Switzerland, 17 August 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to…

Press Release August 17, 2020

Cenobamate Designated Promising Innovative Medicine (PIM) by the UK’s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults

PIM designation is an early indication that cenobamate is a promising candidate for the MHRA’s Early Access to Medicine Scheme Milestone further…

Press Release August 11, 2020

Arvelle to Present at Jefferies Virtual 2020 Healthcare Conference

Zug, Switzerland, 1 June 2020 – Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to…

Press Release June 1, 2020

Arvelle Announces Closing of Final Tranche of Series A Financing Round

Brings the total financing to $207.8m Triggered by successful filing and validation of the MAA for cenobamate Zug, Switzerland, 26 May 2020 –…

Press Release May 26, 2020

Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure control in Adults with Uncontrolled Focal Seizures Published in Neurology 1

28% of patients receiving cenobamate achieved seizure-freedom (zero seizures) during the study’s maintenance phase, versus 9% receiving placebo1 In…

Press Release May 21, 2020

SK Life Science, Inc. Announces US Availability of XCOPRI® (cenobamate tablets) for the Treatment of Partial (Focal) Onset Seizures in Adults with Epilepsy

Arvelle Therapeutics has exclusive rights to develop and commercialize cenobamate in Europe Zug, Switzerland, 12 May 2020 – Arvelle…

Press Release May 12, 2020
Next

Related Articles


  • The Lancet Neurology

    November 13, 2019
    Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published
  • Bioworld

    November 4, 2019
    Arvelle’s CEO Mark Altmeyer Interview
Angelini Pharma Company
+41 (0) 417115882 info.ch@angelinipharma.com
LinkedIn LinkedIn Twitter Twitter
  • Home
  • Privacy Policy
Manage Cookie Consent
We use cookies to optimise your experience and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}